<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38360929</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Feb</Month><Day>15</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Long term outcomes of hyperbaric oxygen therapy in post covid condition: longitudinal follow-up of a randomized controlled trial.</ArticleTitle><Pagination><StartPage>3604</StartPage><MedlinePgn>3604</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">3604</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-53091-3</ELocationID><Abstract><AbstractText>In our previous randomized controlled trial, we documented significant improvements in cognitive, psychiatric, fatigue, sleep, and pain symptoms among long Coronavirus disease 2019 (COVID) patients who underwent hyperbaric oxygen therapy (HBOT). The primary objective of the present study was to evaluate the enduring 1 year long term effects of HBOT on long COVID syndrome. This longitudinal long-term follow-up included 31 patients with reported post COVID-19 cognitive symptoms, who underwent 40 daily sessions of HBOT. Participants were recruited more than one year (486&#x2009;&#xb1;&#x2009;73) after completion of the last HBOT session. Quality of life, assessed using the short form-36 (SF-36) questionnaire revealed, that the long-term results exhibited a similar magnitude of improvement as the short-term outcomes following HBOT across most domains. Regarding sleep quality, improvements were observed in global score and across five sleep domains with effect sizes of moderate magnitude during the short-term evaluation, and these improvements persisted in the long-term assessment (effect size (ES1)&#x2009;=&#x2009;0.47-0.79). In the realm of neuropsychiatric symptoms, as evaluated by the brief symptom inventory-18 (BSI-18), the short-term assessment following HBOT demonstrated a large effect size, and this effect persisted at the long-term evaluation. Both pain severity (ES1&#x2009;=&#x2009;0.69) and pain interference (ES1&#x2009;=&#x2009;0.83), had significant improvements during the short-term assessment post HBOT, which persisted at long term. The results indicate HBOT can improve the quality of life, quality of sleep, psychiatric and pain symptoms of patients suffering from long COVID. The clinical improvements gained by HBOT are persistent even 1 year after the last HBOT session.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hadanny</LastName><ForeName>Amir</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf Harofeh) Medical Center, Zerifin, Israel. amir.had@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Tel-Aviv University, Tel-Aviv, Israel. amir.had@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zilberman-Itskovich</LastName><ForeName>Shani</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf Harofeh) Medical Center, Zerifin, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Catalogna</LastName><ForeName>Merav</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf Harofeh) Medical Center, Zerifin, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elman-Shina</LastName><ForeName>Karin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf Harofeh) Medical Center, Zerifin, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lang</LastName><ForeName>Erez</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf Harofeh) Medical Center, Zerifin, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Finci</LastName><ForeName>Shachar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf Harofeh) Medical Center, Zerifin, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polak</LastName><ForeName>Nir</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf Harofeh) Medical Center, Zerifin, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shorer</LastName><ForeName>Ran</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf Harofeh) Medical Center, Zerifin, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parag</LastName><ForeName>Yoav</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf Harofeh) Medical Center, Zerifin, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Efrati</LastName><ForeName>Shai</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf Harofeh) Medical Center, Zerifin, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sagol School of Neuroscience, Tel-Aviv University, Tel-Aviv, Israel.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006931" MajorTopicYN="Y">Hyperbaric Oxygenation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010146" MajorTopicYN="N">Pain</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Amir Hadanny works for AVIV Scientific LTD. Shai Efrati is a shareholder at AVIV Scientific LTD. LTD. SZI, MC, KES, EL, SF, NP, RS, RS and YP have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>1</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>16</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>15</Day><Hour>23</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38360929</ArticleId><ArticleId IdType="pmc">PMC10869702</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-53091-3</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-53091-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ceban F, et al. Fatigue and cognitive impairment in post-COVID-19 syndrome: A systematic review and meta-analysis. Brain Behav. Immun. 2022;101:93&#x2013;135. doi: 10.1016/j.bbi.2021.12.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2021.12.020</ArticleId><ArticleId IdType="pmc">PMC8715665</ArticleId><ArticleId IdType="pubmed">34973396</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat. Med. 2022;28:1461&#x2013;1467. doi: 10.1038/s41591-022-01840-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01840-0</ArticleId><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D, et al. Risk of long COVID in people infected with severe acute respiratory syndrome coronavirus 2 after 2 doses of a coronavirus disease 2019 vaccine: Community-based, matched cohort study. Open Forum Infect. Dis. 2022;9:ofac464. doi: 10.1093/ofid/ofac464.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac464</ArticleId><ArticleId IdType="pmc">PMC9494414</ArticleId><ArticleId IdType="pubmed">36168555</ArticleId></ArticleIdList></Reference><Reference><Citation>Batiha GE, Al-Kuraishy HM, Al-Gareeb AI, Welson NN. Pathophysiology of post-COVID syndromes: A new perspective. Virol. J. 2022;19:158. doi: 10.1186/s12985-022-01891-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-022-01891-2</ArticleId><ArticleId IdType="pmc">PMC9548310</ArticleId><ArticleId IdType="pubmed">36210445</ArticleId></ArticleIdList></Reference><Reference><Citation>Zilberman-Itskovich S, et al. Hyperbaric oxygen therapy improves neurocognitive functions and symptoms of post-COVID condition: Randomized controlled trial. Sci. Rep. 2022;12:11252. doi: 10.1038/s41598-022-15565-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-15565-0</ArticleId><ArticleId IdType="pmc">PMC9276805</ArticleId><ArticleId IdType="pubmed">35821512</ArticleId></ArticleIdList></Reference><Reference><Citation>Catalogna M, et al. Effects of hyperbaric oxygen therapy on functional and structural connectivity in post-COVID-19 condition patients: A randomized, sham-controlled trial. Neuroimage Clin. 2022;36:103218. doi: 10.1016/j.nicl.2022.103218.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2022.103218</ArticleId><ArticleId IdType="pmc">PMC9528018</ArticleId><ArticleId IdType="pubmed">36208548</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: Major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023;21:133&#x2013;146. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolton MJ, Chapman BP, Van Marwijk H. Low-dose naltrexone as a treatment for chronic fatigue syndrome. BMJ Case Rep. 2020 doi: 10.1136/bcr-2019-232502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2019-232502</ArticleId><ArticleId IdType="pmc">PMC6954765</ArticleId><ArticleId IdType="pubmed">31911410</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman L, et al. Myalgic encephalomyelitis/chronic fatigue syndrome: Essentials of diagnosis and management. Mayo Clin. Proc. 2021;96:2861&#x2013;2878. doi: 10.1016/j.mayocp.2021.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2021.07.004</ArticleId><ArticleId IdType="pubmed">34454716</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledford H. Long-COVID treatments: Why the world is still waiting. Nature. 2022;608:258&#x2013;260. doi: 10.1038/d41586-022-02140-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-022-02140-w</ArticleId><ArticleId IdType="pubmed">35945375</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadanny A, Efrati S. The hyperoxic-hypoxic paradox. Biomolecules. 2020 doi: 10.3390/biom10060958.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom10060958</ArticleId><ArticleId IdType="pmc">PMC7355982</ArticleId><ArticleId IdType="pubmed">32630465</ArticleId></ArticleIdList></Reference><Reference><Citation>Efrati S, Ben-Jacob E. Reflections on the neurotherapeutic effects of hyperbaric oxygen. Expert Rev. Neurother. 2014;14:233&#x2013;236. doi: 10.1586/14737175.2014.884928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14737175.2014.884928</ArticleId><ArticleId IdType="pubmed">24471697</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottfried I, Schottlender N, Ashery U. Hyperbaric oxygen treatment-from mechanisms to cognitive improvement. Biomolecules. 2021 doi: 10.3390/biom11101520.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom11101520</ArticleId><ArticleId IdType="pmc">PMC8533945</ArticleId><ArticleId IdType="pubmed">34680155</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadanny A, et al. Hyperbaric oxygen therapy can induce neuroplasticity and significant clinical improvement in patients suffering from fibromyalgia with a history of childhood sexual abuse-randomized controlled trial. Front. Psychol. 2018;9:2495. doi: 10.3389/fpsyg.2018.02495.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyg.2018.02495</ArticleId><ArticleId IdType="pmc">PMC6304433</ArticleId><ArticleId IdType="pubmed">30618929</ArticleId></ArticleIdList></Reference><Reference><Citation>Efrati S, et al. Hyperbaric oxygen therapy can diminish fibromyalgia syndrome&#x2013;prospective clinical trial. PLoS ONE. 2015;10:e0127012. doi: 10.1371/journal.pone.0127012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0127012</ArticleId><ArticleId IdType="pmc">PMC4444341</ArticleId><ArticleId IdType="pubmed">26010952</ArticleId></ArticleIdList></Reference><Reference><Citation>Ablin JN, et al. Hyperbaric oxygen therapy compared to pharmacological intervention in fibromyalgia patients following traumatic brain injury: A randomized, controlled trial. PLoS ONE. 2023;18:e0282406. doi: 10.1371/journal.pone.0282406.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0282406</ArticleId><ArticleId IdType="pmc">PMC10004612</ArticleId><ArticleId IdType="pubmed">36897850</ArticleId></ArticleIdList></Reference><Reference><Citation>Efrati S, et al. Hyperbaric oxygen induces late neuroplasticity in post stroke patients&#x2013;randomized, prospective trial. PLoS ONE. 2013;8:e53716. doi: 10.1371/journal.pone.0053716.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0053716</ArticleId><ArticleId IdType="pmc">PMC3546039</ArticleId><ArticleId IdType="pubmed">23335971</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadanny A, et al. Cognitive enhancement of healthy older adults using hyperbaric oxygen: A randomized controlled trial. Aging. 2020;12:13740&#x2013;13761. doi: 10.18632/aging.103571.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.103571</ArticleId><ArticleId IdType="pmc">PMC7377835</ArticleId><ArticleId IdType="pubmed">32589613</ArticleId></ArticleIdList></Reference><Reference><Citation>Mudgal SK, et al. Pooled prevalence of long COVID-19 symptoms at 12 months and above follow-up period: A systematic review and meta-analysis. Cureus. 2023;15:e36325. doi: 10.7759/cureus.36325.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.36325</ArticleId><ArticleId IdType="pmc">PMC10108372</ArticleId><ArticleId IdType="pubmed">37077615</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderlind WM, et al. A systematic review of neuropsychological and psychiatric sequalae of COVID-19: Implications for treatment. Curr. Opin. Psychiatry. 2021;34:420&#x2013;433. doi: 10.1097/YCO.0000000000000713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/YCO.0000000000000713</ArticleId><ArticleId IdType="pmc">PMC8183238</ArticleId><ArticleId IdType="pubmed">34016818</ArticleId></ArticleIdList></Reference><Reference><Citation>Benedetti F, et al. Brain correlates of depression, post-traumatic distress, and inflammatory biomarkers in COVID-19 survivors: A multimodal magnetic resonance imaging study. Brain Behav. Immun. Health. 2021;18:100387. doi: 10.1016/j.bbih.2021.100387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbih.2021.100387</ArticleId><ArticleId IdType="pmc">PMC8562046</ArticleId><ArticleId IdType="pubmed">34746876</ArticleId></ArticleIdList></Reference><Reference><Citation>De Paepe B, Smet J, Baeken C, Van Oosterwijck J, Meeus M. A capital role for the brain's insula in the diverse fibromyalgia-associated symptoms. Med. Hypotheses. 2020;143:110077. doi: 10.1016/j.mehy.2020.110077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2020.110077</ArticleId><ArticleId IdType="pubmed">32721793</ArticleId></ArticleIdList></Reference><Reference><Citation>Murga I, Guillen V, Lafuente JV. Cerebral magnetic resonance changes associated with fibromyalgia syndrome. Med. Clin. 2017;148:511&#x2013;516. doi: 10.1016/j.medcli.2017.01.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medcli.2017.01.034</ArticleId><ArticleId IdType="pubmed">28450073</ArticleId></ArticleIdList></Reference><Reference><Citation>Foerster BR, et al. Cerebral blood flow alterations in pain-processing regions of patients with fibromyalgia using perfusion MR imaging. AJNR Am. J. Neuroradiol. 2011;32:1873&#x2013;1878. doi: 10.3174/ajnr.A2614.</Citation><ArticleIdList><ArticleId IdType="doi">10.3174/ajnr.A2614</ArticleId><ArticleId IdType="pmc">PMC4337836</ArticleId><ArticleId IdType="pubmed">21868622</ArticleId></ArticleIdList></Reference><Reference><Citation>Majolo F, et al. Neuropsychiatric disorders and COVID-19: What we know so far. Pharmaceuticals. 2021 doi: 10.3390/ph14090933.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph14090933</ArticleId><ArticleId IdType="pmc">PMC8465079</ArticleId><ArticleId IdType="pubmed">34577633</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar D, et al. Neurological manifestation of SARS-CoV-2 induced inflammation and possible therapeutic strategies against COVID-19. Mol. Neurobiol. 2021;58:3417&#x2013;3434. doi: 10.1007/s12035-021-02318-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-021-02318-9</ArticleId><ArticleId IdType="pmc">PMC7955900</ArticleId><ArticleId IdType="pubmed">33715108</ArticleId></ArticleIdList></Reference><Reference><Citation>Desforges M, Le Coupanec A, Stodola JK, Meessen-Pinard M, Talbot PJ. Human coronaviruses: Viral and cellular factors involved in neuroinvasiveness and neuropathogenesis. Virus Res. 2014;194:145&#x2013;158. doi: 10.1016/j.virusres.2014.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2014.09.011</ArticleId><ArticleId IdType="pmc">PMC7114389</ArticleId><ArticleId IdType="pubmed">25281913</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia MA, et al. Cerebrospinal fluid in COVID-19 neurological complications: Neuroaxonal damage, anti-SARS-Cov2 antibodies but no evidence of cytokine storm. J. Neurol. Sci. 2021;427:117517. doi: 10.1016/j.jns.2021.117517.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2021.117517</ArticleId><ArticleId IdType="pmc">PMC8166041</ArticleId><ArticleId IdType="pubmed">34090021</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R, et al. The spatial and cell-type distribution of SARS-CoV-2 receptor ACE2 in the human and mouse brains. Front. Neurol. 2020;11:573095. doi: 10.3389/fneur.2020.573095.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.573095</ArticleId><ArticleId IdType="pmc">PMC7855591</ArticleId><ArticleId IdType="pubmed">33551947</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Kuraishy HM, Al-Gareeb AI, Alexiou A, Batiha GE. Central effects of ivermectin in alleviation of covid-19-induced dysautonomia. Curr. Drug Targets. 2022;23:1277&#x2013;1287. doi: 10.2174/1389450123666220810102406.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389450123666220810102406</ArticleId><ArticleId IdType="pubmed">35950254</ArticleId></ArticleIdList></Reference><Reference><Citation>Versace V, et al. Intracortical GABAergic dysfunction in patients with fatigue and dysexecutive syndrome after COVID-19. Clin. Neurophysiol. 2021;132:1138&#x2013;1143. doi: 10.1016/j.clinph.2021.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2021.03.001</ArticleId><ArticleId IdType="pmc">PMC7954785</ArticleId><ArticleId IdType="pubmed">33774378</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva Andrade B, et al. Long-COVID and post-COVID health complications: An up-to-date review on clinical conditions and their possible molecular mechanisms. Viruses. 2021 doi: 10.3390/v13040700.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13040700</ArticleId><ArticleId IdType="pmc">PMC8072585</ArticleId><ArticleId IdType="pubmed">33919537</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong SJ. Long COVID or post-COVID-19 syndrome: Putative pathophysiology, risk factors, and treatments. Infect. Dis. 2021;53:737&#x2013;754. doi: 10.1080/23744235.2021.1924397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23744235.2021.1924397</ArticleId><ArticleId IdType="pmc">PMC8146298</ArticleId><ArticleId IdType="pubmed">34024217</ArticleId></ArticleIdList></Reference><Reference><Citation>Oronsky B, et al. A review of persistent post-COVID syndrome (PPCS) Clin. Rev. Allergy Immunol. 2023;64:66&#x2013;74. doi: 10.1007/s12016-021-08848-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-021-08848-3</ArticleId><ArticleId IdType="pmc">PMC7896544</ArticleId><ArticleId IdType="pubmed">33609255</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Kuraishy HM, Al-Gareeb AI, El-Bouseary MM, Sonbol FI, Batiha GE. Hyperviscosity syndrome in COVID-19 and related vaccines: Exploring of uncertainties. Clin. Exp. Med. 2023;23:679&#x2013;688. doi: 10.1007/s10238-022-00836-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10238-022-00836-x</ArticleId><ArticleId IdType="pmc">PMC9128329</ArticleId><ArticleId IdType="pubmed">35608715</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvagno M, et al. The normobaric oxygen paradox-hyperoxic hypoxic paradox: A novel expedient strategy in hematopoiesis clinical issues. Int. J. Mol. Sci. 2022 doi: 10.3390/ijms24010082.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24010082</ArticleId><ArticleId IdType="pmc">PMC9820104</ArticleId><ArticleId IdType="pubmed">36613522</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang JH, Lo T, Mychaskiw G, Colohan A. Mechanisms of hyperbaric oxygen and neuroprotection in stroke. Pathophysiology. 2005;12:63&#x2013;77. doi: 10.1016/j.pathophys.2005.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pathophys.2005.01.003</ArticleId><ArticleId IdType="pubmed">15869872</ArticleId></ArticleIdList></Reference><Reference><Citation>Neubauer RA, James P. Cerebral oxygenation and the recoverable brain. Neurol. Res. 1998;20(Suppl 1):S33&#x2013;36. doi: 10.1080/01616412.1998.11740606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01616412.1998.11740606</ArticleId><ArticleId IdType="pubmed">9584921</ArticleId></ArticleIdList></Reference><Reference><Citation>Tal S, Hadanny A, Sasson E, Suzin G, Efrati S. Hyperbaric oxygen therapy can induce angiogenesis and regeneration of nerve fibers in traumatic brain injury patients. Front. Hum. Neurosci. 2017;11:508. doi: 10.3389/fnhum.2017.00508.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnhum.2017.00508</ArticleId><ArticleId IdType="pmc">PMC5654341</ArticleId><ArticleId IdType="pubmed">29097988</ArticleId></ArticleIdList></Reference><Reference><Citation>Mensah-Kane P, Sumien N. The potential of hyperbaric oxygen as a therapy for neurodegenerative diseases. Geroscience. 2023;45:747&#x2013;756. doi: 10.1007/s11357-022-00707-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11357-022-00707-z</ArticleId><ArticleId IdType="pmc">PMC9886764</ArticleId><ArticleId IdType="pubmed">36525211</ArticleId></ArticleIdList></Reference><Reference><Citation>Boussi-Gross R, et al. Improvement of memory impairments in poststroke patients by hyperbaric oxygen therapy. Neuropsychology. 2015;29:610&#x2013;621. doi: 10.1037/neu0000149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/neu0000149</ArticleId><ArticleId IdType="pubmed">25384125</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadanny A, et al. Hyperbaric oxygen therapy improves neurocognitive functions of post-stroke patients&#x2014;a retrospective analysis. Restor. Neurol. Neurosci. 2020;38:93&#x2013;107. doi: 10.3233/RNN-190959.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/RNN-190959</ArticleId><ArticleId IdType="pmc">PMC7081098</ArticleId><ArticleId IdType="pubmed">31985478</ArticleId></ArticleIdList></Reference><Reference><Citation>Hart BB, et al. Extended follow-up in a randomized trial of hyperbaric oxygen for persistent post-concussive symptoms. Undersea Hyperb. Med. 2019;46:313&#x2013;327. doi: 10.22462/13.15.2019.9.</Citation><ArticleIdList><ArticleId IdType="doi">10.22462/13.15.2019.9</ArticleId><ArticleId IdType="pubmed">31394601</ArticleId></ArticleIdList></Reference><Reference><Citation>Doenyas-Barak K, et al. Hyperbaric oxygen therapy for veterans with treatment-resistant PTSD: A longitudinal follow-up study. Mil. Med. 2022 doi: 10.1093/milmed/usac360.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/milmed/usac360</ArticleId><ArticleId IdType="pubmed">36433746</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandek B, Sinclair SJ, Kosinski M, Ware JE., Jr Psychometric evaluation of the SF-36 health survey in medicare managed care. Health Care Financ. Rev. 2004;25:5&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4194895</ArticleId><ArticleId IdType="pubmed">15493441</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Q, et al. Reliability, validity, and sensitivity of short-form 36 health survey (SF-36) in patients with sick sinus syndrome. Medicine. 2023;102:e33979. doi: 10.1097/MD.0000000000033979.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000033979</ArticleId><ArticleId IdType="pmc">PMC10270486</ArticleId><ArticleId IdType="pubmed">37327281</ArticleId></ArticleIdList></Reference><Reference><Citation>Grassi L, Caruso R, Mitchell AJ, Sabato S, Nanni MG. Screening for emotional disorders in patients with cancer using the Brief Symptom Inventory (BSI) and the BSI-18 versus a standardized psychiatric interview (the World Health Organization Composite International Diagnostic Interview) Cancer. 2018;124:2415&#x2013;2426. doi: 10.1002/cncr.31340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.31340</ArticleId><ArticleId IdType="pubmed">29660109</ArticleId></ArticleIdList></Reference><Reference><Citation>Buysse DJ, et al. Relationships between the Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS), and clinical/polysomnographic measures in a community sample. J. Clin. Sleep Med. 2008;4:563&#x2013;571. doi: 10.5664/jcsm.27351.</Citation><ArticleIdList><ArticleId IdType="doi">10.5664/jcsm.27351</ArticleId><ArticleId IdType="pmc">PMC2603534</ArticleId><ArticleId IdType="pubmed">19110886</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald, D. D. et al. Older adult pain communication and the Brief Pain Inventory Short Form. Pain Manag. Nurs.9, 154&#x2013;159, 159.e151&#x2013;152, 10.1016/j.pmn.2008.03.001 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">19041613</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Fatatry BM, Ibrahim OM, Hussien FZ, Mostafa TM. Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study. Int. J. Colorectal Dis. 2018;33:1675&#x2013;1683. doi: 10.1007/s00384-018-3104-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00384-018-3104-9</ArticleId><ArticleId IdType="pubmed">29931409</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>